Access Pharmaceuticals Announces MuGard Poster Presentation At ASTRO Conference

     Access Pharmaceuticals Announces MuGard Poster Presentation At ASTRO
                                  Conference

PR Newswire

DALLAS and NEW YORK, Sept. 24, 2013

DALLASand NEW YORK, Sept.24, 2013 /PRNewswire/ --ACCESS PHARMACEUTICALS,
INC. (OTCBB: ACCP), an emerging biopharmaceutical company, announced a poster
presentation at the American Society for Radiation Oncology Meeting, September
22-25, 2013, in Atlanta, GA. The poster presentation, co-authored by Access
Pharmaceuticals' Senior Vice President Research and Development, Dr. David
Nowotnik, entitled, "Results from the Multi-Institutional, Randomized,
Double-Blind, Placebo-Controlled Trial to Assess the Efficacy of MuGard^® in
Mitigating Oral Mucositis (OM) in Chemoradiation-Treated Head and Neck Cancer
Patients", discusses the findings from the Company's post-marketing clinical
trial that evaluated the efficacy of MuGard in controlling symptoms caused by
oral mucositis in 120 patients receiving chemoradiation therapy for the
treatment of cancers of the head and neck.

MuGard was shown to be superior to the sham control rinse in mitigating OM
symptoms and delaying OM progression. In the trial, MuGard met the primary
endpoint, achieving a statistically significant reduction in mouth and throat
soreness associated with Oral Mucositis. MuGard also achieved significance in
a secondary endpoint, the measurement of mucositis severity at the end of
radiation treatment using a physician-based assessment of severity.
Additional secondary endpoints where MuGard demonstrated superiority were
reduced opioid use and weight loss.

Commenting on the findings included in the poster presentation, Nowotnik
stated, "The impact of mucositis on patients is significant with particular
affect on their ability to eat and maintain their weight. Due to the oral
pain and discomfort of OM, patients eat less and lose weight as a result.
Previous studies have shown that severe weight loss during chemoradiation
therapy correlates with lower quality of life after therapy and a higher risk
of mortality."

"The reduction of weight loss in the patients using MuGard is an important
result of this study," stated Dr. William Wisbeck, MD of the Providence
Regional Medical Center, Everett, WA. A principal investigator in the clinical
trial and a coauthor on the poster, Dr. Wisbeck continued, "Average weight
loss in patients using MuGard was almost 4kg less than those in the control
group. This magnitude of difference can suggest MuGard will lead to better
clinical outcomes."

About Oral Mucositis: Oral mucositis ("OM") is a debilitating side effect of
some radiation and chemotherapy cancer treatments, characterized by sores and
ulcers in the mouth and throat that make swallowing difficult or impossible.
It is estimated that 97% of patients receiving radiation for head and neck
cancer, 70% of patients receiving stem cell transplantation and up to 40% of
patients receiving conventional chemotherapy develop oral mucositis. The NIH
estimates that there are 400,000 patients diagnosed with OM in the US
annually, but OM is often under-diagnosed and the population at risk is
significantly higher.

About ASTRO: ASTRO is the premier radiation oncology society in the world,
with more than 10,000 members who are physicians, nurses, biologist,
physicists, radiation therapists, dosimetrists and other health care
professionals that specialize in treating patients with radiation therapies.
To learn more about ASTRO, visit www.astro.org.

About MuGard: MuGard^® Mucoadhesive Oral Wound Rinse is indicated for the
management of oral mucositis/stomatitis (that may be caused by radiotherapy
and/or chemotherapy) and all types of oral wounds (mouth sores and injuries),
including aphthous ulcers/canker sores and traumatic ulcers, such as those
caused by oral surgery or ill-fitting dentures or braces. MuGard is available
by prescription only and is contraindicated in patients with known
hypersensitivity to any of the ingredients in the formulation. MuGard was
launched in 2010 after receiving 510(k) clearance from the U.S. Food and Drug
Administration and is marketed by AMAG Pharmaceuticals, Inc. in the United
States.

About Access: Access Pharmaceuticals, Inc. is an emerging biopharmaceutical
company that develops and commercializes proprietary products for the
treatment and supportive care of cancer patients. Access developed MuGard and
is developing multiple products. Access also has other advanced drug delivery
technologies including CobaCyte™-mediated targeted delivery and CobOral-oral
drug delivery, its proprietary nanopolymer delivery technology based on the
natural vitamin B12 uptake mechanism. For additional information on Access
Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within
the meaning of Section 27a of the Securities Act of 1933, as amended, and that
involve risks and uncertainties. These statements include those relating to:
our cash burn rate, clinical trial plans and timelines and clinical results
for MuGard and Cobalamin, our ability to achieve clinical and commercial
success and our ability to successfully develop marketed products. These
statements are subject to numerous risks, including but not limited to Access'
need to obtain additional financing in order to continue the clinical trial
and operations and to the risks detailed in Access' Annual Reports on Form
10-K and other reports filed by Access with the Securities and Exchange
Commission.

Company and Media Contact:
Christine Berni
Director of Investor Relations
Access Pharmaceuticals, Inc.
(212) 786-6208

SOURCE Access Pharmaceuticals, Inc.

Website: http://www.accesspharma.com
 
Press spacebar to pause and continue. Press esc to stop.